Evolution of the Average Target: Ovid Therapeutics Inc.

Evolution of the Target Price: Ovid Therapeutics Inc.

Changes in Analyst Recommendations: Ovid Therapeutics Inc.

e8a29f9cee.yZyWSm6LzHKWbh47g8-siLy88Q7UiaQ6Ay3uCYnrLQ0.js7ffD2zqDXwX3RM0vffwO7-xWmY-eZCUFi6OM-zY2Sfq94mI7r-BewpcQ~26c2e95ac384f6533d60d543f08ff775
03-19 Wedbush Raises Price Target on Ovid Therapeutics to $7 From $5, Keeps Outperform Rating MT
12-11 Roth Capital Initiates Ovid Therapeutics With Buy Rating, $3 Price Target MT
11-17 Leerink Partners Initiates Ovid Therapeutics at Outperform With $5 Price Target MT
11-12 Ovid Therapeutics Q3 revenue slightly beats expectations RE
25-10-09 Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says MT
25-10-06 Wedbush Adjusts Price Target on Ovid Therapeutics to $5 From $3, Maintains Outperform Rating MT
25-10-03 Wedbush Adjusts Ovid Therapeutics Price Target to $5 From $3, Maintains Outperform Rating MT
25-10-03 Ovid Therapeutics Agrees to Financing Deal Worth up to $175 million MT
25-03-12 Wedbush Adjusts Price Target on Ovid Therapeutics to $3 From $4, Keeps Outperform Rating MT
25-01-29 Oppenheimer Upgrades Ovid Therapeutics to Outperform From Perform, $4 Price Target MT
24-06-18 Oppenheimer Downgrades Ovid Therapeutics to Market Perform MT
24-06-18 B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating MT
24-06-18 BTIG Adjusts Price Target on Ovid Therapeutics to $5 From $11, Maintains Buy Rating MT
24-06-18 HC Wainwright Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating MT
24-06-18 Citigroup Adjusts Price Target on Ovid Therapeutics to $1.20 From $3.50, Maintains Neutral Rating MT
24-06-17 Top Midday Decliners MT
24-06-17 Wedbush Lowers PT on Ovid Therapeutics to $4 From $8 After Soticlestat Missed Endpoints in Phase 3 Studies; Maintains Outperform Rating MT
24-04-30 B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target MT
24-04-29 HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target MT
23-12-21 BTIG Initiates Ovid Therapeutics With Buy Rating, Price Target is $11 MT
23-10-13 Oppenheimer Initiates Coverage on Ovid Therapeutics With Outperform Rating, $8 Price Target MT
23-06-14 JonesTrading Initiates Ovid Therapeutics at Buy With $6 Price Target MT
22-05-20 Citigroup Adjusts Ovid Therapeutics' Price Target to $2.40 from $4, Keeps Neutral Rating MT
21-08-25 OVID THERAPEUTICS : Citigroup Adjusts Ovid Therapeutics' Price Target to $4 from $4.50, Keeps Neutral Rating MT
21-04-20 OVID THERAPEUTICS : Cantor Fitzgerald Downgrades Ovid Therapeutics to Neutral from Overweight, Adjusts PT to $4 from $8 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+114.55%
+10.79%
+23.51%
+35.78%
+90.61%
+41.85%
+35.91%
-9.62%
-21.53%
+31.01%
Average +35.29%
Weighted average by Cap. +26.46%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.550USD
Average target price
5.471USD
Spread / Average Target
+114.55%
High Price Target
7.000USD
Spread / Highest target
+174.51%
Low Price Target
4.000USD
Spread / Lowest Target
+56.86%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
Roth Capital Partners
Leerink Partners
Oppenheimer
Citigroup
HC Wainwright
BTIG
B. Riley
JonesTrading Institutional Services
Cantor Fitzgerald
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.550USD
Average target price
5.471USD
Spread / Average Target
+114.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock
  4. Consensus Ovid Therapeutics Inc.